Insider Selling: Becton, Dickinson and Company (NYSE:BDX) VP Sells 443 Shares of Stock

Becton, Dickinson and Company (NYSE:BDXGet Rating) VP Thomas J. Spoerel sold 443 shares of the company’s stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $260.00, for a total transaction of $115,180.00. Following the sale, the vice president now directly owns 1,058 shares in the company, valued at approximately $275,080. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of NYSE:BDX traded down $2.57 during trading on Thursday, reaching $252.28. The stock had a trading volume of 5,658 shares, compared to its average volume of 933,283. The company has a market capitalization of $71.92 billion, a P/E ratio of 40.20, a PEG ratio of 3.49 and a beta of 0.64. The company has a current ratio of 1.52, a quick ratio of 1.04 and a debt-to-equity ratio of 0.72. The firm’s 50-day simple moving average is $257.92 and its 200 day simple moving average is $258.49. Becton, Dickinson and Company has a one year low of $235.13 and a one year high of $280.62.

Becton, Dickinson and (NYSE:BDXGet Rating) last announced its quarterly earnings data on Thursday, May 5th. The medical instruments supplier reported $3.18 EPS for the quarter, beating the consensus estimate of $2.98 by $0.20. The firm had revenue of $5.01 billion during the quarter, compared to analyst estimates of $4.78 billion. Becton, Dickinson and had a net margin of 9.59% and a return on equity of 14.91%. Becton, Dickinson and’s revenue was up 2.1% on a year-over-year basis. During the same period last year, the firm posted $3.19 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 11.19 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 30th. Shareholders of record on Thursday, June 9th will be given a dividend of $0.87 per share. This represents a $3.48 dividend on an annualized basis and a yield of 1.38%. The ex-dividend date is Wednesday, June 8th. Becton, Dickinson and’s dividend payout ratio is presently 54.89%.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Rehmann Capital Advisory Group increased its holdings in shares of Becton, Dickinson and by 10.5% during the 1st quarter. Rehmann Capital Advisory Group now owns 1,929 shares of the medical instruments supplier’s stock valued at $513,000 after purchasing an additional 184 shares in the last quarter. Insight Advisors LLC PA acquired a new stake in Becton, Dickinson and in the 1st quarter valued at $421,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Becton, Dickinson and by 34.7% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 42,590 shares of the medical instruments supplier’s stock worth $11,226,000 after purchasing an additional 10,983 shares during the last quarter. City State Bank boosted its stake in Becton, Dickinson and by 8.8% during the 1st quarter. City State Bank now owns 2,101 shares of the medical instruments supplier’s stock worth $559,000 after purchasing an additional 170 shares during the last quarter. Finally, Kestra Private Wealth Services LLC boosted its stake in Becton, Dickinson and by 17.7% during the 1st quarter. Kestra Private Wealth Services LLC now owns 4,160 shares of the medical instruments supplier’s stock worth $1,107,000 after purchasing an additional 626 shares during the last quarter. 86.58% of the stock is owned by institutional investors.

A number of equities research analysts recently issued reports on BDX shares. StockNews.com raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Thursday, June 2nd. Wells Fargo & Company increased their target price on shares of Becton, Dickinson and from $275.00 to $285.00 and gave the company an “equal weight” rating in a research note on Friday, April 1st. Morgan Stanley raised their price target on shares of Becton, Dickinson and from $293.00 to $295.00 and gave the stock an “overweight” rating in a research note on Monday, April 11th. Bank of America assumed coverage on shares of Becton, Dickinson and in a research note on Tuesday, March 1st. They issued a “neutral” rating on the stock. Finally, Piper Sandler dropped their target price on shares of Becton, Dickinson and from $265.00 to $255.00 in a report on Thursday, May 5th. Five analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Becton, Dickinson and has an average rating of “Hold” and a consensus price target of $276.43.

About Becton, Dickinson and (Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Featured Articles

Insider Buying and Selling by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.